HumanAI TriMatrix Analyzer Platform
The AI powered TriMatrix AnalyzerTM Platform is the future of targeted protein degradation. With our cutting-edge molecular glue technology, you can selectively degrade proteins that were previously inaccessible to traditional drug targeting methods. This innovative platform promises to be a powerful tool for drug discovery and creating new therapies for a range of diseases. Partner with us and discover the possibilities with TriMatrix AnalyzerTM.
Protein Degradation by Ubiquitin Proteosome pathway
The ubiquitin proteosome pathway is an essential cellular process that targets proteins for degradation. E3 ligase is a key enzyme in this pathway and is responsible for binding both the target protein and ubiquitin, initiating the degradation process. At Ligronbio, we study the mechanisms of this process for variuos E3 ligases to develop innovative solutions for protein degradation by molecular glues
Exploring the Undruggable degron targets
Undruggable proteins have long been a challenge in the search for new treatments for cancer and CNS diseases. At LigronBio, we are leading the way in developing therapies for undruggable degron targets, which are proteins that are traditionally difficult to target with drugs. Our team of skilled researchers is dedicated to finding new and innovative ways to treat these diseases, and we believe that our work has the potential to make a lasting impact on the lives of patients.
Protein Degradation by Molecular Glue
Molecular glues induces the recruitment of a neo-substrate to an E3 ligase for the formation of ternary complex that do not normally interact leading to proteolysis of the target which is a crucial aspect of Protein degradation. Our cutting-edge AI powered TriMatrix AnalyzerTM platform enables us to design molecular glues that form effective ternary complexes with E3 ligase and substrate of interest pushing the boundaries of scientific discovery.
